Charter CEO buys $1.2M at 52-week low after 60% drawdown

Charter's director bought $1.2M of CHTR at $173.11 on Monday. Discretionary. The stock sits three dollars off its 52-week low, down 60% from last April's high of $437. He now owns $3M total. The timing stands out.

Charter reports May 2, twelve days out. Last quarter they missed by 6.1%, and the stock dropped 11.8% the week after. The director walked in with six figures while the stock trades at basement levels ahead of earnings. He's been on the board since 2016. He knows what's in the pipeline.

Charter director buys $175K near 52-week low after 60% crash

Board member Nair Balan just bought $175K of CHTR at $173, within $1 of the 52-week low. The stock is down 60% from its peak as cord-cutting accelerates and broadband growth stalls. This discretionary purchase shows up when the board member is catching a falling knife, not a bounce.

Horizon Kinetics adds TPL at $437, 20% below 52w high

Horizon Kinetics just added $436 to their TPL position. Discretionary buy, not pre-planned. The firm has made 32 consecutive purchases over two years without a single sale. Earnings drop in 8 days.

GPC refinances credit facility and reports annual meeting results

Genuine Parts refinanced a $1 billion term loan with fresh borrowing at favorable rates while shareholders approved standard governance measures at their annual meeting. The auto parts distributor is restructuring debt at $105 per share, down 30% from its 52-week high. The timing suggests management sees better credit terms now than waiting, though shares remain flat for the year.

CBRE signs material definitive agreement

CBRE just locked in $3 billion of committed credit through 2030, replacing its existing facility with better terms and extended maturity. The commercial real estate giant is refinancing while it still has pricing power, not because it needs the money. This gives management flexibility to fund acquisitions or weather a downturn in CRE markets without scrambling for liquidity later.

McKesson refinances credit facility, upsizes revolver to $4.5B

McKesson refinanced its credit facility, replacing a $3.5B revolver with a new $4B facility while extending the maturity to 2030. The healthcare distributor is locking in capacity at better terms while its stock trades near all-time highs following strong pharma distribution volumes. The extra $500M gives McKesson flexibility for bolt-on M&A in specialty pharma or oncology services.

Market Context